Analysis and Opinion: Aurinia Pharma ($AUPH) — Lupkynis, Aritinercept, and the flexibility of the autoimmune pipeline

Investment thesis

Why I See Inefficiencies at Aurinia Pharmaceuticals

The area of autoimmune diseases is, together with oncology, the therapeutic area with the highest number of highest density of clinical development in biopharma at this time. This is no coincidence; these are chronic, highly prevalent conditions, with patients requiring lifelong treatment, and where the standard of care has not undergone any substantial changes for decades. When a truly differentiated drug enters this space, the market knows how to reward it—Benlysta, Skyrizi, and Dupixent are examples of what happens when biology and commercial execution align.

We're talking about a company that ended 2025 with $271M in sales of its only product on the market, growing at a year-over-year rate of 251% in the third quarter, with 1Q4Q136M in operating cash flow, more than three times as many as the previous year, $398M in box with no significant debt burden and an active share buyback program that has returned nearly 1.4 billion to shareholders over the past twelve months. A company like this, in any other sector, would trade at a significant premium.

Valuation Scenarios

My price scenarios for $AUPH

Company Analysis

Aurinia Pharmaceuticals Inc. ($AUPH)

Aurinia Pharmaceuticals is a Canadian-American biopharmaceutical company focused exclusively on autoimmune diseases with a high unmet medical need. It is not an early-stage company seeking financing from the market based on a promising pipeline, has a commercially available, FDA-approved product that is growing at a double-digit rate and generating actual operating cash flow. That is a critical distinction in an industry where most companies of similar market capitalization continue to burn through capital with no prospect of profitability.

Its main asset, Lupkynis (voclosporin), was approved by the FDA in January 2021 as the first oral therapy for the treatment of adults with active lupus nephritis. The distinction between voclosporin and traditional calcineurin inhibitors is not merely a marketing ploy—its more predictable pharmacokinetic profile, with no need for intensive level monitoring, plus the renal protection documented in the AURORA 1 and AURORA 2 studies, are real clinical arguments that nephrologists consider when prescribing.

The second asset under development, Aritinercept (AUR200), holds the potential for a re-rating. It is a dual BAFF and APRIL inhibitor designed with a unique molecular architecture: it employs a BCMA-based binding domain, with greater intrinsic affinity for APRIL compared to the TACI-engineered approach used by other dual inhibitors, and an IgG4 Fc with minimal effector function. If the clinical profile confirms the signals observed in Phase 1, the addressable TAM for Aritinercept would be orders of magnitude larger than that of Lupkynis.

Pipeline and clinical analysis

Lupkynis holds on, ritinercept starts to take effect

Lupkynis has been on the market for five years, and long-term data supports the business case. According to the Spherix Global Insights audit (March 2026), approximately 1 in 5 lupus nephritis patients managed by nephrologists in the U.S. currently receives a calcineurin inhibitor, and Lupkynis clearly dominates that class.. The 2025 ACR guidelines reinforced this stance by recommending triple therapy as first-line treatment—a regulatory shield that protects growth.

The competitive landscape became more complicated in October 2025 with the approval of Gazyva (obinutuzumab) from Roche/Genentech. The key point is that Gazyva and Lupkynis do not compete directly for the same patients: Lupkynis retains real advantages in oral access, out-of-pocket costs, and the absence of eGFR restrictions that do apply to Gazyva. Real-world data show that competitive pressure falls mainly on Benlysta and off-label rituximab.

For aritinercept, the results of the Phase 1 SAD study (June 2025) exceeded expectations. In 61 healthy volunteers, single subcutaneous doses resulted in mean reductions of up to 48% in IgA, 55% in IgM and 20% in IgG at day 28., with no adverse events of grade 3 or higher, no SAEs, and no discontinuations. A comparison with other dual BAFF/APRIL inhibitors currently in development shows that aritinercept, at equivalent doses, produces reductions in IgA and IgM that are equal to or greater than those of the other agents.

The most likely candidates for the ongoing trials are:

Fundamental analysis

Lupkynis' business expansion, cash generation, and pipeline flexibility

Aurinia is trading around $16.25 with a market capitalization of ~$2.14B. With $398M in the pipeline, the implied enterprise value is approximately $1.74B—between 5 and 6 times projected 2026 sales, a reasonable valuation if Aritinercept demonstrates clinical efficacy but a challenging one if key catalysts fail to materialize.

Identified catalysts

Visibility in Lupkynis and binary events in Aritinercept

Risks of the thesis

Real risks I identify in $AUPH

Technical Analysis

$AUPH — Range-bound consolidation and imminent breakout

The daily chart for AUPH shows a phase of prolonged accumulation in the $6–8 zone, a sharp rally between July and October 2025 that drove the price from lows of $6.55 to highs of $16.54 (ATH), and a subsequent consolidation in the range of 1Q14–16.50 which has been under construction for several months. The current price of ~$16.25 is at the upper end of that range, just a few cents shy of the cycle's all-time high.

The key resistance level is $16.42-16.54, the cycle highs that the price has reached and rejected on at least two occasions. A clean breakout at that level, accompanied by volume, would confirm the upward trend and pave the way toward $20–22 as the next significant technical target.

The MACD (12,26,9) shows a positive but contracting histogram (0.0277) — bullish momentum is present but slowing. The The RSI (14) stands at 65.07, in the upper-middle range. It is not technically overbought, but the stock is at a price level where fundamental catalysts take on greater relative importance than pure momentum in driving further gains.

Synthesis

Why am I holding the CALL STK $20 position on $AUPH?

Aurinia Pharmaceuticals ($AUPH) is at that awkward point for the market: too «real» to be treated as a speculative biotech stock, yet still lacking the recognition that established platforms receive. Not because it lacks growth, but because it is still perceived as a one-product story. And that is where the inefficiency lies.

From a financial standpoint, AUPH does not fit the typical profile of the sector. With ~$271 million in sales in 2025 (+251% YoY), ~1Q4Q136M in operating cash flow, and ~1Q4Q398M in cash, the balance sheet is more typical of a profitable mid-cap company than of a developing biotech firm. At current multiples (~5–6x forward sales), the market is valuing the existing business, but still places little value on the pipeline. That mismatch is key: the downside is partially offset by a business that is already up and running, while the upside depends on aritinercept beginning to «exist» in terms of market perception.

The main risk lies not in the pipeline, but in the current core business. The launch of Gazyva introduces competitive pressure in lupus nephritis, and although early data suggest it does not directly compete with Lupkynis in first-line treatment, any slowdown in prescribing will be interpreted as a loss of market share. In a concentrated market, the narrative shifts quickly if growth slows.